Valence 로고
인기
로그인
Loading data for BSX — first visit, this takes a few seconds.

관심목록에 추가

Boston Scientific Corpora...

NYSE: BSX · 실시간 가격 · USD
51.43
-0.40 (-0.77%)
종가 기준: Aug 17, 2026, 8:00 PM

Boston Scientific Corporation (BSX) Stock Price, Analysis & Data

-0.77%

데이터 없음

매수호가n/a
시가총액74.53B
매출 (ttm)21B
순이익 (ttm)3.67B
베타0.57
EPS (ttm)2.45
P/E (ttm)20.99
선행 P/E14.96
P/B (ttm)2.98
P/S (ttm)3.55
Earnings DateOct 28, 2026
매도호가n/a
거래량12,903,637
평균 거래량 (20일)21,006,829
시가51.71
전일 종가51.83
일중 범위51.24 - 52.06
52주 범위42.20 - 109.50
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

BSX 소개

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and the...

[더 보기]
산업 Medical Devices
섹터 Healthcare
IPO 일자 May 19, 1992
직원 수 59,000
상장 거래소 NYSE
티커 BSX
웹사이트 https://www.bostonscientific.com
전체 기업 정보

재무 실적

2025년 Boston Scientific의 매출은 20.07B로, 전년 16.75B 대비 19.87% 증가했습니다. 순이익은 2.9B로, 56.31% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 undefined명의 투자의견을 종합하면 BSX 주식의 평균 등급은 "undefined"입니다. 12개월 목표주가는 null로, 최근 주가 대비 0% 하락 여력입니다.

주가 전망

어닝 서프라이즈

Boston Scientific가 Jul 29, 2026에 분기 실적을 발표했습니다:
  • 매출 n/a 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
  • EPS 0.86 예상치 상회 0.03, 및 14.67% 전년 대비 성장.

    • 다음 실적 발표

    Boston Scientific Corporation의 실적 발표 예정일은 Oct 28, 2026, 장 시작 전입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1일 전 · Insider Monkey

    Boston Scientific (BSX) Faces Growth Concerns in Key Medical Device Franchises

    Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 14.69% in t...

    news image

    3일 전 · Simply Wall St.

    Boston Scientific (BSX), What Is Behind The Latest Investor Attention?

    Boston Scientific completes multi year buyback and what it means for investors Boston Scientific (BSX) has completed a multi year share repurchase program, buying back 39,922,436 shares for about US$2...

    news image

    3일 전 · Simply Wall St.

    Is Boston Scientific’s (BSX) Buyback at Odds with Its Lower 2026 Growth Guidance?

    In the June quarter, Boston Scientific completed a share repurchase of 39,922,436 shares, equal to 2.69% of its stock, for US$2,000.11 million under the buyback first announced in December 2020, while...

    news image

    4일 전 · Simply Wall St.

    Is Boston Scientific (BSX) Still Undervalued After A 50% Fall?

    Boston Scientific stock has fallen about 50% over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach both suggest the shares may be trad...

    news image

    4일 전 · Zacks

    Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

    Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

    2 페이지 중 1